NOVA EYE MEDICAL (EYE) - Revolutionizing Glaucoma Treatment: Managing Director Tom Spurling on iTrack™ Innovation, Strategic Global Expansion, and Future Growth Plans

ASX BRIEFS

Send us a text

Unlock the secrets behind Nova Eye Medical's remarkable 44% global sales growth as we sit down with Tom Spurling, the visionary Managing Director who’s leading a revolution in glaucoma treatment. Tom shares how their innovative iTrack™ Advanced Canaloplasty device is changing the game, offering a stent-free, minimally invasive solution that’s capturing the attention of ophthalmic surgeons worldwide. Discover how Nova Eye is making strategic moves in the US, China, and Europe despite facing supply chain challenges, and learn how they’re setting the stage for future success in the global medical technology landscape.
Join us as we explore Nova Eye Medical's ambitious plans for the financial year 2025, focusing on growth in key markets and achieving financial break-even in their glaucoma division. Tom gives us a closer look at the company’s strategic priorities and the growing adoption of their cutting-edge technology. Whether you’re intrigued by the future of glaucoma care or curious about the dynamics of scaling a medical tech company, this episode is brimming with insights and strategies from a leader who’s at the forefront of ophthalmic innovation.